A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Dry Age-related Macular Degeneration

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

62 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-07-30

Study Completion Date

2022-03-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is designed to investigate the safety, PK/PD, biomarker and early clinical effects of repeat GEM103 IVT injections.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

First in Human Study to Evaluate the Safety and Tolerability of GEM103 in Geographic Atrophy Secondary to Dry Age Related Macular Degeneration

NCT04246866

COMPLETED PHASE1

A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Neovascular Age-related Macular Degeneration

NCT04684394

Neovascular Age-related Macular Degeneration Retinal Disease Retinal Degeneration +1 more

TERMINATED PHASE2

A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of RO7303359 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

NCT04615325

Geographic Atrophy

COMPLETED PHASE1

A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

NCT06635148

Geographic Atrophy Macular Degeneration

RECRUITING PHASE2

Intravitreal AAVCAGsCD59 for Advanced Dry Age-related Macular Degeneration (AMD) With Geographic Atrophy (GA)

NCT04358471

WITHDRAWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a Phase 2a, multi-center, open-label, multiple dose study in subjects with geographic atrophy (GA) secondary to dry Age-related Macular Degeneration (dry AMD) to investigate the safety, PK/PD, biomarker and early clinical effect of GEM103 repeat IVT injections.

Subjects will undergo clinical and ophthalmic assessments for determination of inclusion in the study. Subjects who participated in the Phase 1 Study (GEM-CL-10301) as well as treatment naïve subjects that did not participate in the GEM-CL-10301 Study and who meet all eligibility criteria will be enrolled.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dry Age-related Macular Degeneration Geographic Atrophy Macular Degeneration Retinal Disease Retinal Degeneration

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort with Genetic Profile A

Subjects will have Genetic Profile A.

Intervention: Biological: GEM103.

Group Type EXPERIMENTAL

GEM103

Intervention Type DRUG

Biological

Cohort with Genetic Profile B

Subjects will have Genetic Profile B.

Intervention: Biological: GEM103

Group Type EXPERIMENTAL

GEM103

Intervention Type DRUG

Biological

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GEM103

Biological

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. At least 50 years old at the time of signed informed consent.
2. Must have one of the following genetic profiles:

1. Genetic Profile A.
2. Genetic Profile B.
3. BCVA in the study eye of 24 to 83 letters using ETDRS Chart Visual Acuity (VA) Scale (approximately equivalent to Snellen VA of 20/25 to 20/320).
4. Confirmed diagnosis of GA in the study eye where total size of all GA lesions in the study eye must be within 0.5 to 15.01- and 7- disc areas.
5. Sufficiently clear ocular media and able to cooperate with ophthalmic visual function testing and anatomic assessment in the study eye.
6. Understands the full nature and purpose of the study and provides informed consent prior to initiation of any study procedure; all subjects with a reproductive potential must agree to use effective contraceptive methods through the end of study (EOS) Visit.

Exclusion Criteria

1. Presence of the following ocular conditions - in the study eye:

1. Any history of exudative Age-related Macular Degeneration or choroidal neovascularization.
2. Any active ocular disease or condition that could confound the assessment of the macula or be a contraindication to IVT injection.
3. Any intraocular surgery, with the exception of stable intraocular lens replacement surgery more than 3 months prior to consent.
4. Aphakia or complete absence of the posterior capsule.
5. History of laser therapy to the macula or fundus or extensive laser to the retina.
6. Prior corneal transplant.
2. Presence of any of the following ocular conditions - in either eye:

1. History of herpetic infection.
2. Concurrent disease that could require medical or surgical intervention during the study period.
3. Active uveitis and/or vitritis (grade: trace or above).
4. History of idiopathic or autoimmune-associated uveitis.
5. Active blepharitis, conjunctivitis, keratitis, episcleritis, scleritis, or endophthalmitis.
6. Any ophthalmologic condition that reduces the clarity of the media and that, in the opinion of the Investigator, interferes with ophthalmologic examination.
3. In the opinion of the Investigator, the subject has any prior or ongoing medical condition (e.g., ocular other than dry AMD, systemic, psychiatric) or clinically significant screening laboratory value that may present a safety risk, interfere with study compliance or study follow-up, or confound data interpretation throughout the follow-up period.
4. Female subjects must not be pregnant or lactating, nor plan to become pregnant during the study.
5. Current use of medications known to be toxic to the lens, retina, or optic nerve.
6. Use of any investigational new drug or other experimental treatment in the last 6 months, and/or receipt of any prior gene therapy (e.g., AAV) or ocular device implantation (other than PCIOL placement following cataract surgery)

Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No